Share on StockTwits

Regado Biosciences (NASDAQ:RGDO) was downgraded by equities research analysts at Jefferies Group from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, TheFlyOnTheWall.com reports. They currently have a $1.50 target price on the stock, down from their previous target price of $7.50. Jefferies Group’s price target would indicate a potential downside of 47.18% from the company’s current price.

Regado Biosciences (NASDAQ:RGDO) traded down 57.08% during mid-day trading on Monday, hitting $1.219. The stock had a trading volume of 3,850,099 shares. Regado Biosciences has a 52-week low of $2.22 and a 52-week high of $14.10. The stock has a 50-day moving average of $2.73 and a 200-day moving average of $6.31. The company’s market cap is $41.0 million.

Regado Biosciences (NASDAQ:RGDO) last announced its earnings results on Monday, August 11th. The company reported ($0.63) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.51) by $0.12. Analysts expect that Regado Biosciences will post $-2.20 EPS for the current fiscal year.

A number of other firms have also recently commented on RGDO. Analysts at Deutsche Bank downgraded shares of Regado Biosciences from a “buy” rating to a “hold” rating in a research note on Monday. They now have a $2.00 price target on the stock, down previously from $14.00. Separately, analysts at Cowen and Company downgraded shares of Regado Biosciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 13th. Finally, analysts at Needham & Company LLC downgraded shares of Regado Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, July 7th. They now have a $13.00 price target on the stock. Two research analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the stock. Regado Biosciences presently has a consensus rating of “Hold” and an average price target of $5.58.

Regado Biosciences, Inc is a biopharmaceutical company focused on the discovery and development of actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.